The pan-RAS inhibitor daraxonrasib led to an unprecedented doubling of overall survival compared with chemotherapy for patients with pancreatic ductal adenocarcinoma in a phase III study. The data, presented at the American Society of Clinical Oncology Annual Meeting, cement the drug as a new standard-of-care for the second-line treatment for metastatic disease and motivate further trials of RAS-targeted therapies.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: